| P50 | author | Logan A. Walsh | Q55071123 |
| | Martin G Dalin | Q63865121 |
| P2093 | author name string | Lu Wang | |
| | Jorge S Reis-Filho | |
| | David B Solit | |
| | Michael F Berger | |
| | Ken-Wing Lee | |
| | Timothy A Chan | |
| | Vladimir Makarov | |
| | Qingguo Wang | |
| | Alan L Ho | |
| | Joshua Armenia | |
| | Ian Ganly | |
| | Luc G T Morris | |
| | Alexis Desrichard | |
| | Nora Katabi | |
| | Snjezana Dogan | |
| | Deepa Ramaswami | |
| | Lyndsay West | |
| | Nikolaus D Schultz | |
| P2860 | cites work | Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 |
| | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| | Fast and accurate short read alignment with Burrows-Wheeler transform | Q24653853 |
| | Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer | Q26772969 |
| | Fusion oncogenes in salivary gland tumors: molecular and clinical consequences | Q27000115 |
| | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
| | Integrative clinical genomics of advanced prostate cancer | Q27853170 |
| | Comprehensive genomic characterization of head and neck squamous cell carcinomas | Q28256121 |
| | Molecular characterization of apocrine salivary duct carcinoma | Q28257895 |
| | A framework for variation discovery and genotyping using next-generation DNA sequencing data | Q29547262 |
| | STAR: ultrafast universal RNA-seq aligner | Q29615052 |
| | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 |
| | Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. | Q30459163 |
| | Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study | Q80227564 |
| | Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options | Q83663739 |
| | Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data | Q30574894 |
| | Inferring tumour purity and stromal and immune cell admixture from expression data | Q30674996 |
| | Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials | Q30783484 |
| | Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. | Q33983489 |
| | Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. | Q34111469 |
| | Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer | Q34216102 |
| | High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma | Q34436470 |
| | Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion | Q34499044 |
| | What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). | Q34514469 |
| | Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. | Q34714945 |
| | HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies | Q34974436 |
| | Androgen receptor status is highly conserved during tumor progression of breast cancer | Q35836387 |
| | Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database | Q35915236 |
| | Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts | Q36623116 |
| | Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma | Q36629205 |
| | Trastuzumab for the treatment of salivary duct carcinoma | Q36714388 |
| | Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients | Q36874710 |
| | The mutational landscape of adenoid cystic carcinoma | Q37003447 |
| | Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification | Q37015111 |
| | ABL1 fusion genes in hematological malignancies: a review | Q37857340 |
| | Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes | Q38033677 |
| | TERT promoter mutations in cancer development | Q38198430 |
| | Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, | Q38370247 |
| | PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation | Q39933516 |
| | An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen | Q40313659 |
| | Identification of molecular apocrine breast tumours by microarray analysis. | Q42478400 |
| | Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma | Q42936492 |
| | FOXA1 mutations in hormone-dependent cancers | Q43247422 |
| | A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. | Q44525947 |
| | 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy | Q45124788 |
| | Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required? | Q46581449 |
| | Mammary analog secretory carcinoma, low-grade salivary duct carcinoma, and mimickers: a comparative study. | Q48170512 |
| | Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. | Q53170699 |
| | Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. | Q54226554 |
| | Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry | Q73165722 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Salivary duct carcinoma | Q7404867 |
| P304 | page(s) | 4623-4633 | |
| P577 | publication date | 2016-04-21 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer | |
| P478 | volume | 22 | |